Category - Feature

Feature

UNITY Biotechnology developing therapeutics to slow, halt or reverse diseases of aging

UNITY Biotechnology’s (NASDAQ:UBX) current focus is on developing medicines to selectively eliminate or modulate senescent cells and to provide transformative benefit in age-related ophthalmologic and neurologic...

September 14, 2021

Feature

Bombi Biomics fighting superbugs with amphibian-derived anti-microbial peptides

Closely-held Bombi Biomics of the Netherlands has developed a technology known as Bombilysin with the potential to kill bacteria from the outside shell in contrast to conventional antibiotics that typically are intended...

August 31, 2021

Feature

Anebulo Pharma addressing cannabinoid intoxication as legalization grows

Anebulo Pharmaceuticals (NASDAQ:ANEB) is developing a novel antidote for cannabinoid intoxication and, longer term, other indications related to abuse and addiction.

August 24, 2021

Feature

Lucid Psycheceuticals focusing on Total Brain Health

Lucid Psycheceuticals’ next generation approach to total brain health is targeting the interface between mental health and neurodegenerative disorders with therapeutic products inspired by psychedelics and new chemical...

August 17, 2021

Feature

Taming cytokine storm syndrome with Jim Joyce of Sigyn Therapeutics

As a co-founder, chairman and CEO of Sigyn Therapeutics (pronounced Sig-en) (OTCMarkets:SIGY), a medical device company developing a blood purification system to treat life-threatening inflammatory conditions, including...

August 10, 2021

Feature

Altamira in strategic repositioning to develop RNA therapeutics

Altamira Therapeutics (NASDAQ:CYTO) is using its recent acquisition of closely-held Trasir Therapeutics as a steppingstone for a strategic repositioning to focus on development of RNA therapeutics, while in the medium...

August 3, 2021

Feature

LENZ Therapeutics readies pivotal trial of aceclidine to treat presbyopia

With a new, experienced management team and a $47-million series A financing in place, closely-held LENZ Therapeutics is gearing up for a pivotal trial of its aceclidine once-daily eye drop to treat presbyopia, the...

July 27, 2021

Feature

Asensus Surgical building bridge from laparoscopy to robotic surgery

Asensus Surgical (NYSE American:ASXC) is digitizing the interface between surgeons and patients to pioneer a new era of Performance-Guided Surgery with its Senhance Surgical System.

July 20, 2021

Feature

Har Grover talks up GeneTether TNT platform

As CEO of closely-held GeneTether, Har Grover is tackling the emerging potential of gene editing, which has come alive in the past few years. As an entrepreneur, investor, senior executive and strategist with over 30...

July 13, 2021

Feature

Sio Gene Therapies developing CNS-targeted gene therapies

Sio Gene Therapies (NASDAQ:SIOX) is pushing the boundaries of gene therapy to develop treatments for three debilitating neurodegenerative diseases, including clinical-stage product candidates in rare fatal pediatric...

July 6, 2021

Category - Feature

UNITY Biotechnology developing therapeutics to slow, halt or reverse diseases of aging

Bombi Biomics fighting superbugs with amphibian-derived anti-microbial peptides

Anebulo Pharma addressing cannabinoid intoxication as legalization grows

Lucid Psycheceuticals focusing on Total Brain Health

Taming cytokine storm syndrome with Jim Joyce of Sigyn Therapeutics

Altamira in strategic repositioning to develop RNA therapeutics

LENZ Therapeutics readies pivotal trial of aceclidine to treat presbyopia

Asensus Surgical building bridge from laparoscopy to robotic surgery

Har Grover talks up GeneTether TNT platform

Sio Gene Therapies developing CNS-targeted gene therapies

General

More